$NLSP
NLS Pharmaceutics Ltd. Stock $nlsp

$nlsp Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000121390023036920 Filed on May 05, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.362M	$6.506M	$5.941M
YoY Change	-43.42%	9.5%	170.08%
% of Gross Profit
Research & Development	$3.433M	$8.977M	$5.919M
YoY Change	-42.01%	51.65%	5844.42%
% of Gross Profit
Depreciation & Amortization	$5.710K	$11.41K	$5.030K
YoY Change	13.52%	13.51%
% of Gross Profit
Operating Expenses	$6.794M	$15.48M	$11.86M
YoY Change	-42.72%	30.54%	415.82%
Operating Profit		-$15.48M
YoY Change		30.54%
Interest Expense	-$81.64K	-$90.82K	-$85.45K
YoY Change	-4.46%	6.28%	-84.8%
% of Operating Profit
Other Income/Expense, Net	-$56.40K	$10.05K
YoY Change		-157.99%
Pretax Income	-$7.855M	-$16.50M	-$11.95M
YoY Change	-34.25%	38.08%	317.48%
Income Tax
% Of Pretax Income
Net Earnings	-$7.855M	-$16.50M	-$11.95M
YoY Change	-34.25%	38.08%	317.48%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.84
Diluted Earnings Per Share	-$0.33	-$0.84	-$1.004M
COMMON SHARES
Basic Shares Outstanding	32.43M shares	19.68M shares
Diluted Shares Outstanding		19.68M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.948M	$8.948M	$5.431M
YoY Change	64.76%	64.76%	5934.67%
Cash & Equivalents	$8.948M	$8.948M	$5.431M
Short-Term Investments
Other Short-Term Assets	$256.8K	$256.8K	$253.4K
YoY Change	1.33%	1.33%	533.5%
Inventory
Prepaid Expenses	$298.0K		$292.0K
Receivables
Other Receivables
Total Short-Term Assets	$9.246M	$9.246M	$5.723M
YoY Change	61.56%	61.56%	2761.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.10K	$18.10K	$29.51K
YoY Change	-38.66%	-38.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.14K	$12.14K	$12.04K
YoY Change	0.86%	0.83%	-98.73%
Total Long-Term Assets	$30.25K	$30.24K	$41.55K
YoY Change	-27.21%	-27.22%	-95.89%
TOTAL ASSETS
Total Short-Term Assets	$9.246M	$9.246M	$5.723M
Total Long-Term Assets	$30.25K	$30.24K	$41.55K
Total Assets	$9.277M	$9.277M	$5.765M
YoY Change	60.92%	60.92%	376.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.373M	$2.373M	$1.737M
YoY Change	36.63%	36.63%	-56.68%
Accrued Expenses	$986.4K	$986.4K	$666.5K
YoY Change	48.01%	48.01%	-53.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$3.360M	$3.360M	$2.403M
YoY Change	39.79%	39.79%	-66.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$2.636M	$2.636M	$2.819M
YoY Change	-6.48%	-6.48%	5.18%
Total Long-Term Liabilities	$2.636M	$2.636M	$2.819M
YoY Change	-6.48%	-6.48%	-5.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.360M	$3.360M	$2.403M
Total Long-Term Liabilities	$2.636M	$2.636M	$2.819M
Total Liabilities	$5.996M	$5.996M	$5.222M
YoY Change	14.81%	14.81%	-48.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.20M		-$41.71M
YoY Change	39.55%
Common Stock	$668.6K		$344.4K
YoY Change	94.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$29.50K
YoY Change
Treasury Stock Shares			1.475M shares
Shareholders Equity	$3.281M	$3.281M	$542.4K
YoY Change
Total Liabilities & Shareholders Equity	$9.277M	$9.277M	$5.765M
YoY Change	60.92%	60.92%	376.42%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$7.855M	-$16.50M	-$11.95M
YoY Change	-34.25%	38.08%	317.48%
Depreciation, Depletion And Amortization	$5.710K	$11.41K	$5.030K
YoY Change	13.52%	13.51%
Cash From Operating Activities	-$6.214M	-$13.88M	-$5.203M
YoY Change	19.44%	-7.07%	2501.35%
INVESTING ACTIVITIES
Capital Expenditures	$0.00		-$6.800K
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00		-$6.800K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.912M	$3.549M
YoY Change		-91.48%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.81M	$17.40M	3.549M
YoY Change	289.13%	-14.46%	5814.33%
NET CHANGE
Cash From Operating Activities	-6.214M	-$13.88M	-5.203M
Cash From Investing Activities	0.000		-6.800K
Cash From Financing Activities	13.81M	$17.40M	3.549M
Net Change In Cash	7.595M	$3.517M	-1.661M
YoY Change	-557.26%	-34.41%	1086.36%
FREE CASH FLOW
Cash From Operating Activities	-$6.214M	-$13.88M	-$5.203M
Capital Expenditures	$0.00		-$6.800K
Free Cash Flow	-$6.214M	-$13.88M	-$5.196M
YoY Change	19.59%	-6.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17396669	usd
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39957
CY2022	dei	Entity Registrant Name EntityRegistrantName	NLS PHARMACEUTICS LTD.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	V8
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	The Circle 6
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	8058
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Zurich
CY2022	dei	Entity Address Country EntityAddressCountry	CH
CY2020	us-gaap	Depreciation Depreciation		usd
CY2022	dei	Security12b Title Security12bTitle	Common shares, nominal value CHF 0.02 per share
CY2022	dei	Trading Symbol TradingSymbol	NLSP
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32428893	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1358
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers AG
CY2022	dei	Auditor Location AuditorLocation	Zurich, Switzerland
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8948400	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5431202	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	297998	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	291954	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9246398	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	5723156	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18102	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29510	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12143	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12044	usd
CY2022Q4	us-gaap	Assets Assets	9276643	usd
CY2021Q4	us-gaap	Assets Assets	5764710	usd
CY2022Q4	nlsp	Accounts Payable Including Related Party AccountsPayableIncludingRelatedParty	53365	usd
CY2021Q4	nlsp	Accounts Payable Including Related Party AccountsPayableIncludingRelatedParty	62231	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2373276	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1737013	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4107	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6877	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	986437	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	666449	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3359713	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2403462	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2499969	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2499969	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	136122	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	318891	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5995804	usd
CY2021Q4	us-gaap	Liabilities Liabilities	5222322	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32428893	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32428893	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16223389	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16223389	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	668555	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	344445	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	29497	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60864530	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42084954	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58201455	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41705775	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50791	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-151739	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3280839	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	542388	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9276643	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5764710	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8976643	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5919452	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99580	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6505721	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5941169	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2199790	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	15482364	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	11860621	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	2299370	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15482364	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-11860621	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-2299370	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10045	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17323	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-328365	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	95211	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	48100	usd
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	86792	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	5655	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	20034	usd
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	146908	usd
CY2022	nlsp	Loss On Conversion Of Debts LossOnConversionOfDebts	-922495	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-16495680	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-11946078	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-2861435	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	nlsp	Defined Pension Plan Adjustments DefinedPensionPlanAdjustments	-100948	usd
CY2021	nlsp	Defined Pension Plan Adjustments DefinedPensionPlanAdjustments	132358	usd
CY2020	nlsp	Defined Pension Plan Adjustments DefinedPensionPlanAdjustments	683	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16394732	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12078436	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2862118	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19682643	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11901636	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-6170950	usd
CY2020	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	24911	usd
CY2020	nlsp	Beneficial Conversion Feature On Related Party Convertible Loan BeneficialConversionFeatureOnRelatedPartyConvertibleLoan	24100	usd
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax	-683	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2861435	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-8984057	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10054657	usd
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	6742638	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1149550	usd
CY2021	nlsp	Issuance Of Common Shares In Equity Transaction IssuanceOfCommonSharesInEquityTransaction	3548581	usd
CY2021	nlsp	Issuance Of Common Shares Partial Commitment Fee IssuanceOfCommonSharesPartialCommitmentFee	59455	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax	-132358	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11946078	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	542388	usd
CY2022	nlsp	Issuance Of Common Shares In Registered Direct Offering Net IssuanceOfCommonSharesInRegisteredDirectOfferingNet	1911513	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2047208	usd
CY2022	nlsp	Issuance Of Prefunded Warrants Net IssuanceOfPrefundedWarrantsNet	5348882	usd
CY2022	nlsp	Issuance Of Common Shares In At The Market Atm Financing IssuanceOfCommonSharesInAtTheMarketATMFinancing	30993	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23692	usd
CY2022	nlsp	Issuance Of Common Shares In Private Placement Offerings Net IssuanceOfCommonSharesInPrivatePlacementOfferingsNet	7275549	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	2472616	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	22730	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax	100948	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16495680	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3280839	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16495680	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11946078	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2861435	usd
CY2022	nlsp	Periodic Pension Costs PeriodicPensionCosts	34142	usd
CY2021	nlsp	Periodic Pension Costs PeriodicPensionCosts	-47183	usd
CY2020	nlsp	Periodic Pension Costs PeriodicPensionCosts	-20085	usd
CY2022	us-gaap	Depreciation Depreciation	11408	usd
CY2021	nlsp	Payment On Bridge Loan PaymentOnBridgeLoan	-670380	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	583443	usd
CY2021	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	3548582	usd
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	249306	usd
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	113130	usd
CY2021	us-gaap	Depreciation Depreciation	10050	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	22730	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-77714	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	67008	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	41611	usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	72188	usd
CY2022	nlsp	Loss On Conversion Of Debt LossOnConversionOfDebt	922495	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-698116	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	188954	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3477	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-21804	usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13482	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	636263	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2269460	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1497123	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	20121	usd
CY2021	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-313342	usd
CY2020	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	137826	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	319989	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-334045	usd
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	446129	usd
CY2022	nlsp	Increase Decrease In Other Long Term Liabilitie IncreaseDecreaseInOtherLongTermLiabilitie	47679	usd
CY2021	nlsp	Increase Decrease In Other Long Term Liabilitie IncreaseDecreaseInOtherLongTermLiabilitie	38919	usd
CY2020	nlsp	Increase Decrease In Other Long Term Liabilitie IncreaseDecreaseInOtherLongTermLiabilitie	24343	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13879371	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14936044	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-729386	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39560	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39560	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	11001569	usd
CY2022	nlsp	Proceeds From The Issuance Of Common Shares In Atm Financing ProceedsFromTheIssuanceOfCommonSharesInATMFinancing	30993	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1911513	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7275549	usd
CY2022	nlsp	Proceeds From The Issuance Of Prefunded Warrants Net ProceedsFromTheIssuanceOfPrefundedWarrantsNet	5348882	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1530000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23692	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	704160	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1980200	usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	6742638	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1149550	usd
CY2021	nlsp	Proceeds From Bridge Loans ProceedsFromBridgeLoans	108610	usd
CY2021	nlsp	Payment On Swiss Government Loans PaymentOnSwissGovernmentLoans	-277537	usd
CY2021	nlsp	Payment On Second Credit Facility PaymentOnSecondCreditFacility	150000	usd
CY2021	nlsp	Payment On Convertible Loans PaymentOnConvertibleLoans	-420020	usd
CY2021	nlsp	Payment On Convertible Loans Related Party PaymentOnConvertibleLoansRelatedParty	-111730	usd
CY2020	nlsp	Proceeds From Swiss Government Loan ProceedsFromSwissGovernmentLoan	262137	usd
CY2020	nlsp	Proceeds From Bridge Loan ProceedsFromBridgeLoan	-565650	usd
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	686701	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20337839	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	503522	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-100	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-24744	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99308	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3517198	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5337491	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-126556	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5431202	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93711	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	220267	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8948400	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5431202	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93711	usd
CY2022	nlsp	Cash Paid For Interest CashPaidForInterest	13248	usd
CY2021	nlsp	Cash Paid For Interest CashPaidForInterest	339932	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	704160	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	946912	usd
CY2021	nlsp	Issuance Of Common Shares To Consultant For Payment Of Expenses IssuanceOfCommonSharesToConsultantForPaymentOfExpenses	50000	usd
CY2021	nlsp	Issuance Of Common Shares To Yorkville For Partial Payment Of Commitment Fees IssuanceOfCommonSharesToYorkvilleForPartialPaymentOfCommitmentFees	59455	usd
CY2022	nlsp	Debt Discount On Convertible Loans DebtDiscountOnConvertibleLoans	67008	usd
CY2020	nlsp	Debt Discount On Convertible Loans DebtDiscountOnConvertibleLoans	39496	usd
CY2020	nlsp	Debt Discount On Related Party Loans DebtDiscountOnRelatedPartyLoans	30030	usd
CY2021Q1	nlsp	Initial Public Offering Units InitialPublicOfferingUnits	4819277	shares
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4.15
CY2021Q1	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	Each unit consisted of one common share and one warrant to purchase one common share (the “Warrants”).
CY2021Q1	nlsp	Gross Proceeds GrossProceeds	17000000	usd
CY2021Q1	nlsp	Additional Purchase Share AdditionalPurchaseShare	722891	shares
CY2021Q1	nlsp	Additional Warrants Share AdditionalWarrantsShare	722891	shares
CY2021Q1	nlsp	Warrant Offering Per Share WarrantOfferingPerShare	0.01
CY2021Q1	nlsp	Warrant Purchase Common Share WarrantPurchaseCommonShare	722891	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.15
CY2022Q4	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	58200000	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	16300000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	8900000	usd
CY2022	us-gaap	Results Of Operations Sales Or Transfers To Entitys Other Operations ResultsOfOperationsSalesOrTransfersToEntitysOtherOperations	18500000	usd
CY2022Q4	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	230000	usd
CY2022	nlsp	Stockholders Equity Stock Split StockholdersEquityStockSplit	The Company has access to the funds under SEDA with some limitations, including YA’s ownership cannot exceed a maximum of 9.99% of the outstanding common shares and the Company cannot issue common shares to YA in excess of the common shares registered on its registration statement.
CY2022	nlsp	Description Of Purchase Agreement DescriptionOfPurchaseAgreement	the Company entered a securities purchase agreement with BVF Partners L.P, (“BVF”) whereby the Company and BVF agreed that, until the 30th day following receipt of the official written minutes from the end of the Phase 2 meeting to be held by the Company with the U.S. Food and Drug Administration (the “Election Deadline”), among other closing conditions, BVF shall have the right to purchase at a second closing (the “Second Closing”) up to $20 million in units (the “Units”), with each Unit consisting of one common share and/or pre-funded warrants to purchase one common share, as well as receive a warrant to purchase up to 150% of the number of common shares and/or pre-funded warrant shares purchased in the Second Closing, at a purchase price of $1.50 per Unit, it being understood that the Company cannot issue fractional shares. The warrants will have a term of five years, will have an exercise price of $2.03 per share and will be exercisable for pre-funded warrants if, at their expiration, BVF will be unable to purchase common shares due to its beneficial ownership limitation of a maximum of 9.99%. The Second Closing is at the discretion of BVF.
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of these financial statements, the Company’s significant estimates include the valuation allowance related to the Company’s deferred tax assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk include cash. At December 31, 2022 and 2021, substantially all of the cash balances are deposited in one banking institution. At various times, the Company has deposits in financial institutions which are in excess of federally insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	nlsp	Tax Benefits More Likely To Be Recognized Percentage TaxBenefitsMoreLikelyToBeRecognizedPercentage	0.50	pure
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	13297916	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5409746	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1474853	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50205	shares
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1530000	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2022Q4	nlsp	Vendor Prepayments VendorPrepayments	65739	usd
CY2021Q4	nlsp	Vendor Prepayments VendorPrepayments	37538	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	41243	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	38551	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	36496	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	187446	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	154520	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	28419	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	297998	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	291954	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	39560	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	39560	usd
CY2022	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1	21458	usd
CY2021	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1	10050	usd
CY2022Q4	us-gaap	Property Plant And Equipment Owned Gross PropertyPlantAndEquipmentOwnedGross	18102	usd
CY2021Q4	us-gaap	Property Plant And Equipment Owned Gross PropertyPlantAndEquipmentOwnedGross	29510	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11408	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10050	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	285398	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	244245	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	13000	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	16954	usd
CY2022Q4	nlsp	Due To Related Party Expenses DueToRelatedPartyExpenses	4107	usd
CY2021Q4	nlsp	Due To Related Party Expenses DueToRelatedPartyExpenses	6877	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	149496	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	137002	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	510678	usd
CY2021Q4	nlsp	Accrued Commitment Fee AccruedCommitmentFee	200000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	23758	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	61371	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	986437	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	666449	usd
CY2022Q1	us-gaap	Receivable From Officers And Directors For Issuance Of Capital Stock ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock	704160	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.039	pure
CY2022Q4	us-gaap	Percentage Of Unamortized Film Costs PercentageOfUnamortizedFilmCosts	0.20	pure
CY2022	nlsp	Equity Financing Round Amount EquityFinancingRoundAmount	6000000	usd
CY2022	nlsp	Aggregate Percentage AggregatePercentage	0.10	pure
CY2022	nlsp	Common Shares Divided Per Share CommonSharesDividedPerShare	0.497
CY2022	nlsp	Aggregate Share AggregateShare	307844	shares
CY2022	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.497
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	67008	usd
CY2022Q4	nlsp	Converted Common Share ConvertedCommonShare	2516429	shares
CY2022Q4	nlsp	Warrants Shares WarrantsShares	1258215	shares
CY2022Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.7
CY2022Q4	nlsp	Issuance Term IssuanceTerm	P5Y
CY2022Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2472616	usd
CY2022Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	922495	usd
CY2022	nlsp	Nonrefundable Upfront Payment NonrefundableUpfrontPayment	2500000	usd
CY2022	nlsp	Receive Nonrefundable Milestone Payments ReceiveNonrefundableMilestonePayments	16000000	usd
CY2022	nlsp	Estimated Total Transaction Price EstimatedTotalTransactionPrice	2500000	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	2500000	usd
CY2022	nlsp	Long Term Deferred Revenue LongTermDeferredRevenue	2500000	usd
CY2021	nlsp	Long Term Deferred Revenue LongTermDeferredRevenue	2500000	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	39667	usd
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	48641	usd
CY2020	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	25206	usd
CY2022	us-gaap	Interest Costs Incurred InterestCostsIncurred	2743	usd
CY2021	us-gaap	Interest Costs Incurred InterestCostsIncurred	732	usd
CY2020	us-gaap	Interest Costs Incurred InterestCostsIncurred	2992	usd
CY2022	nlsp	Expected Return On Assets ExpectedReturnOnAssets	-12196	usd
CY2021	nlsp	Expected Return On Assets ExpectedReturnOnAssets	-6314	usd
CY2020	nlsp	Expected Return On Assets ExpectedReturnOnAssets	-4249	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	-72600	usd
CY2020	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	-5810	usd
CY2022	nlsp	Actuarial Loss Outside Corridor Recognized ActuarialLossOutsideCorridorRecognized	3091	usd
CY2021	nlsp	Actuarial Loss Outside Corridor Recognized ActuarialLossOutsideCorridorRecognized	983	usd
CY2022	nlsp	Past Service Cost Recognized PastServiceCostRecognized	2855	usd
CY2022	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	2298	usd
CY2021	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	3141	usd
CY2020	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	1946	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	nlsp	Net Periodic Pension Cost NetPeriodicPensionCost	-34142	usd
CY2021	nlsp	Net Periodic Pension Cost NetPeriodicPensionCost	47183	usd
CY2020	nlsp	Net Periodic Pension Cost NetPeriodicPensionCost	20085	usd
CY2021Q4	nlsp	Projected Benefit Obligation Beginning And Ending ProjectedBenefitObligationBeginningAndEnding	927369	usd
CY2020Q4	nlsp	Projected Benefit Obligation Beginning And Ending ProjectedBenefitObligationBeginningAndEnding	273675	usd
CY2022	nlsp	Projected Benefit Obligation Service Cost ProjectedBenefitObligationServiceCost	39667	usd
CY2021	nlsp	Projected Benefit Obligation Service Cost ProjectedBenefitObligationServiceCost	48641	usd
CY2022	nlsp	Projected Benefit Obligation Interest Cost ProjectedBenefitObligationInterestCost	2743	usd
CY2021	nlsp	Projected Benefit Obligation Interest Cost ProjectedBenefitObligationInterestCost	732	usd
CY2022	nlsp	Projected Benefit Obligation Transfersin Andout Net ProjectedBenefitObligationTransfersinAndoutNet	-209035	usd
CY2021	nlsp	Projected Benefit Obligation Transfersin Andout Net ProjectedBenefitObligationTransfersinAndoutNet	442557	usd
CY2022	nlsp	Projected Benefit Obligation Actuarialgain Loss ProjectedBenefitObligationActuarialgainLoss	-152048	usd
CY2021	nlsp	Projected Benefit Obligation Actuarialgain Loss ProjectedBenefitObligationActuarialgainLoss	167864	usd
CY2022	nlsp	Projected Benefit Obligation Currency Conversion Adjustments ProjectedBenefitObligationCurrencyConversionAdjustments	-23959	usd
CY2021	nlsp	Projected Benefit Obligation Currency Conversion Adjustments ProjectedBenefitObligationCurrencyConversionAdjustments	-6100	usd
CY2022Q4	nlsp	Projected Benefit Obligation Beginning And Ending ProjectedBenefitObligationBeginningAndEnding	584737	usd
CY2021Q4	nlsp	Projected Benefit Obligation Beginning And Ending ProjectedBenefitObligationBeginningAndEnding	927369	usd
CY2021Q4	nlsp	Plan Assets Beginning And Ending PlanAssetsBeginningAndEnding	608478	usd
CY2020Q4	nlsp	Plan Assets Beginning And Ending PlanAssetsBeginningAndEnding	95406	usd
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-51764	usd
CY2021	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	70634	usd
CY2022	nlsp	Plan Assets Employer Contributions PlanAssetsEmployerContributions	37468	usd
CY2021	nlsp	Plan Assets Employer Contributions PlanAssetsEmployerContributions	34062	usd
CY2022	nlsp	Plan Assets Participant Contributions PlanAssetsParticipantContributions	20608	usd
CY2021	nlsp	Plan Assets Participant Contributions PlanAssetsParticipantContributions	20738	usd
CY2022	nlsp	Plan Assets Transfersin Andout Net PlanAssetsTransfersinAndoutNet	-150129	usd
CY2021	nlsp	Plan Assets Transfersin Andout Net PlanAssetsTransfersinAndoutNet	392021	usd
CY2022	nlsp	Plan Assets Administration Expenses PlanAssetsAdministrationExpenses	-2299	usd
CY2021	nlsp	Plan Assets Administration Expenses PlanAssetsAdministrationExpenses	-3141	usd
CY2022	nlsp	Plan Assets Currency Conversion Adjustments PlanAssetsCurrencyConversionAdjustments	-13747	usd
CY2021	nlsp	Plan Assets Currency Conversion Adjustments PlanAssetsCurrencyConversionAdjustments	-1242	usd
CY2022Q4	nlsp	Plan Assets Beginning And Ending PlanAssetsBeginningAndEnding	448615	usd
CY2021Q4	nlsp	Plan Assets Beginning And Ending PlanAssetsBeginningAndEnding	608478	usd
CY2022Q4	nlsp	Accrued Pension Liability AccruedPensionLiability	136122	usd
CY2021Q4	nlsp	Accrued Pension Liability AccruedPensionLiability	318891	usd
CY2021	nlsp	Loss On Conversion Of Debt LossOnConversionOfDebt		usd
CY2022Q4	nlsp	Accrued Pension Liability AccruedPensionLiability	136122	usd
CY2021Q4	nlsp	Accrued Pension Liability AccruedPensionLiability	318891	usd
CY2022Q4	nlsp	Projected Benefit Obligations Percentage Rate ProjectedBenefitObligationsPercentageRate	0.10	pure
CY2022	nlsp	Amortization Cost AmortizationCost	0	usd
CY2021	nlsp	Amortization Cost AmortizationCost	0	usd
CY2022Q4	nlsp	Unrecognized Pension Costs UnrecognizedPensionCosts	50792	usd
CY2021Q4	nlsp	Unrecognized Pension Costs UnrecognizedPensionCosts	151739	usd
CY2021Q4	nlsp	Net Lossin Beginning And Ending NetLossinBeginningAndEnding	151739	usd
CY2020Q4	nlsp	Net Lossin Beginning And Ending NetLossinBeginningAndEnding	19381	usd
CY2022	nlsp	Other Gainloss During The Period OtherGainlossDuringThePeriod	-88088	usd
CY2021	nlsp	Other Gainloss During The Period OtherGainlossDuringThePeriod	103544	usd
CY2022	nlsp	Other Prior Year Gainloss Recognized In Period OtherPriorYearGainlossRecognizedInPeriod	-3091	usd
CY2021	nlsp	Other Prior Year Gainloss Recognized In Period OtherPriorYearGainlossRecognizedInPeriod	-983	usd
CY2022	nlsp	Effect Of Settlement EffectOfSettlement	-6913	usd
CY2022Q4	nlsp	Net Lossin And Ending NetLossinAndEnding	53647	usd
CY2021Q4	nlsp	Net Lossin And Ending NetLossinAndEnding	121942	usd
CY2022	nlsp	Amortization Of Prior Service Cost AmortizationOfPriorServiceCost	-2856	usd
CY2021	nlsp	Amortization Of Prior Service Cost AmortizationOfPriorServiceCost	29797	usd
CY2022Q4	nlsp	Prior Service Cost Ending PriorServiceCostEnding	-2856	usd
CY2021Q4	nlsp	Prior Service Cost Ending PriorServiceCostEnding	29797	usd
CY2022Q4	nlsp	Total Unrecognized Pension Cost End Of Period TotalUnrecognizedPensionCostEndOfPeriod	50791	usd
CY2021Q4	nlsp	Total Unrecognized Pension Cost End Of Period TotalUnrecognizedPensionCostEndOfPeriod	151739	usd
CY2022Q4	nlsp	Weighted Average Discount Rate WeightedAverageDiscountRate	0.0225	pure
CY2021Q4	nlsp	Weighted Average Discount Rate WeightedAverageDiscountRate	0.003	pure
CY2022Q4	nlsp	Rate Of Increase In Compensation Level RateOfIncreaseInCompensationLevel	0.0025	pure
CY2021Q4	nlsp	Rate Of Increase In Compensation Level RateOfIncreaseInCompensationLevel	0	pure
CY2022Q4	nlsp	Interest Credit Rate On Savings Accountsin Dollars InterestCreditRateOnSavingsAccountsinDollars	0.0225	pure
CY2021Q4	nlsp	Interest Credit Rate On Savings Accountsin Dollars InterestCreditRateOnSavingsAccountsinDollars	0.01	pure
CY2022Q4	nlsp	Expected Longterm Rate Of Return On Plan Assets ExpectedLongtermRateOfReturnOnPlanAssets	0.0295	pure
CY2021Q4	nlsp	Expected Longterm Rate Of Return On Plan Assets ExpectedLongtermRateOfReturnOnPlanAssets	0.02	pure
CY2022Q4	nlsp	Weighted Average Inflation Rate WeightedAverageInflationRate	0.0085	pure
CY2021Q4	nlsp	Weighted Average Inflation Rate WeightedAverageInflationRate	0.006	pure
CY2022Q4	nlsp	Accumulated Benefit Obligation AccumulatedBenefitObligation	584737	usd
CY2021Q4	nlsp	Accumulated Benefit Obligation AccumulatedBenefitObligation	927369	usd
CY2020	nlsp	Loss On Conversion Of Debt LossOnConversionOfDebt		usd
CY2021Q1	nlsp	License Consideration LicenseConsideration	250000	usd
CY2021Q1	nlsp	Milestone Payments Due Description MilestonePaymentsDueDescription	(i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company’s product candidate reaching $250 million in cumulative sales.
CY2022Q4	nlsp	Issued Common Shares IssuedCommonShares	32428893	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5747126	shares
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.87
CY2022Q4	nlsp	Warrants To Purchase WarrantsToPurchase	5747127	shares
CY2022Q4	nlsp	Cash Placement Fee CashPlacementFee	700000	usd
CY2022	nlsp	Aggregate Gross Proceeds Percentage AggregateGrossProceedsPercentage	0.05	pure
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	20000000
CY2022	nlsp	Number Of Common Shares Percentage NumberOfCommonSharesPercentage	1.50	pure
CY2022	nlsp	Share Capital And Public Offerings Description ShareCapitalAndPublicOfferingsDescription	Pursuant to the purchase agreement, the Company agreed to grant BVF the right to participate in future offerings of the Company’s securities for a period from the first closing (the “First Closing”) until the earlier of (i) the 30-month anniversary of the initial closing date or (ii) until such time that BVF retains beneficial ownership of less than 9.9% of the issued and outstanding Common Shares. on the same terms, conditions and price provided for in the subsequent financing or the right to purchase a comparable security with a beneficial ownership limitation. In addition, the Company agreed to grant BVF the right to nominate one member to the Company’s Board of Directors and shall continue to recommend to its shareholders to elect such member for a period from the First Closing until such time that BVF retains beneficial ownership of less than 9.9% of the issued and outstanding common shares.
CY2022Q4	nlsp	Share Capital And Public Offerings Description ShareCapitalAndPublicOfferingsDescription	the Company closed on a securities purchase agreement for the issuance in a private placement offering of (i) 5,194,802 common shares at a purchase price of $0.77 per share, and (ii) warrants to purchase up to an aggregate of 2,597,401 common shares at an exercise of $0.70 per share. The Company’s Chairman of the Board of Directors, Ronald Hafner, purchased 324,675 common shares in the offering and the Company’s Chief Medical Officer, George Apostol, purchased 1,298,701 common shares in the offering.
CY2022	nlsp	Cash Placement Fee Percentage CashPlacementFeePercentage	0.035	pure
CY2022	nlsp	Aggregate Principal Balance AggregatePrincipalBalance	1530000	usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2516429	shares
CY2022	nlsp	Warrants To Purchase WarrantsToPurchase	1258215	shares
CY2022	nlsp	Exercise Price Per Share ExercisePricePerShare	0.7
CY2022Q2	nlsp	Common Shares CommonShares	3015384	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.04
CY2022Q1	nlsp	Sales Agreement Description SalesAgreementDescription	the Company entered into an ATM Sales Agreement (the “Sales Agreement”) with Virtu, as sales agent. Pursuant to the terms of the Sales Agreement, the Company may issue and sell from time to time its common shares through Virtu, acting as its sales agent, or directly to Virtu, acting as principal. On March 31, 2022, the Company sold 22,000 common shares through the Sales Agreement for approximately $31,000, net. Pursuant to the Company’s prospectus supplement filed on April 13, 2022, the Company may issue and sell its common shares having an aggregate offering price of up to $230,000 pursuant to the Sales Agreement.
CY2022	nlsp	Commission Rate Percentage CommissionRatePercentage	0.03	pure
CY2022Q4	nlsp	Purchase Of Common Shares PurchaseOfCommonShares	574712	shares
CY2022Q4	nlsp	Expire Period ExpirePeriod	P5Y
CY2022Q4	us-gaap	Payments For Proceeds From Real Estate Partnership Investment Net PaymentsForProceedsFromRealEstatePartnershipInvestmentNet	272892	usd
CY2022Q4	nlsp	Aggregate Common Shares AggregateCommonShares	2597400	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.7
CY2022Q4	nlsp	Expire Period ExpirePeriod	P5Y
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	806510	shares
CY2022Q3	nlsp	Aggregate Common Shares AggregateCommonShares	307844	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.5
CY2022Q3	nlsp	Expire Period ExpirePeriod	P2Y
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	67008	shares
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	534966	usd
CY2022Q2	nlsp	Aggregate Common Shares AggregateCommonShares	3150000	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.04
CY2022Q2	nlsp	Expire Period ExpirePeriod	P5Y
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1477835	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5409746	usd
CY2022	nlsp	Proceeds To Issuance Warrants ProceedsToIssuanceWarrants	14819913	usd
CY2022	nlsp	Stock Issued During Period Options Exercised StockIssuedDuringPeriodOptionsExercised	-1184616	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19045043	usd
CY2022	nlsp	Common Share Warrants CommonShareWarrants	10605284	usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1474853	shares
CY2021Q4	nlsp	Diluted Shares Percentage DilutedSharesPercentage	0.15	pure
CY2022	nlsp	Share Based Compensation Arrangement By Share Based Payment Award Grant Term ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantTerm	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1333123	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.23
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1333123	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.23
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	50000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1283123	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y10M24D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y10M24D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1333123	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	50000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.22
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1283123	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.25
CY2022Q4	us-gaap	Share Price SharePrice	1.29
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	154270	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	22730	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.036	pure
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	306508	usd
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M
CY2022	nlsp	Description Of Income Tax Description DescriptionOfIncomeTaxDescription	The Company has Swiss tax loss carryforwards of $32.4 million as of December 31, 2022 (December 31, 2021: $23.6 million) of which $15.5 million will expire within the next five years, and $16.9 million will expire between 2028 - 2029.
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3485242	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2504647	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	264997	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	264997	usd
CY2021	nlsp	Other Deferred Tax Net OtherDeferredTaxNet	-24086	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3750239	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2745558	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1004681	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1119614	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	384488	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1004681	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1119614	usd
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	384488	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1004681	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1119614	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	384488	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.106	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.106	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.09	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.048	pure
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.039	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.058	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.07	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.129	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	nlsp	Net Operating Loss NetOperatingLoss	9700000	usd
CY2022	us-gaap	Payments For Fees PaymentsForFees	100841	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	12500	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	10000	shares
CY2022Q4	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	4400	chf
CY2022Q4	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	270	usd
CY2022Q4	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	250	chf
CY2022Q4	nlsp	Exceeding Hours Per Month ExceedingHoursPerMonth	PT20H
CY2022Q4	us-gaap	Payments For Fees PaymentsForFees	4042	usd
CY2022Q4	us-gaap	Payments For Fees PaymentsForFees	3740	chf
CY2022Q4	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	50000	usd
CY2022Q4	nlsp	Accounts Payable Including Related Party AccountsPayableIncludingRelatedParty	53365	usd
CY2021Q4	nlsp	Accounts Payable Including Related Party AccountsPayableIncludingRelatedParty	62231	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4107	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6877	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16223389	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16223389	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32428893	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32428893	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021	nlsp	Loss On Conversion Of Debts LossOnConversionOfDebts		usd
CY2020	nlsp	Loss On Conversion Of Debts LossOnConversionOfDebts		usd
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6960000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6960000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11901636	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19682643	shares
CY2021	nlsp	Capital Increase For Financing Transactions CapitalIncreaseForFinancingTransactions		usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	nlsp	Debt Discount On Convertible Loans DebtDiscountOnConvertibleLoans		usd
CY2021	nlsp	Proceeds From The Issuance Of Common Shares In Atm Financing ProceedsFromTheIssuanceOfCommonSharesInATMFinancing		usd
CY2020	nlsp	Proceeds From The Issuance Of Common Shares In Atm Financing ProceedsFromTheIssuanceOfCommonSharesInATMFinancing		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2021	nlsp	Proceeds From The Issuance Of Prefunded Warrants Net ProceedsFromTheIssuanceOfPrefundedWarrantsNet		usd
CY2020	nlsp	Proceeds From The Issuance Of Prefunded Warrants Net ProceedsFromTheIssuanceOfPrefundedWarrantsNet		usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans		usd
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	nlsp	Proceeds From Bridge Loans ProceedsFromBridgeLoans		usd
CY2020	nlsp	Proceeds From Bridge Loans ProceedsFromBridgeLoans		usd
CY2022	nlsp	Payment On Swiss Government Loans PaymentOnSwissGovernmentLoans		usd
CY2020	nlsp	Payment On Swiss Government Loans PaymentOnSwissGovernmentLoans		usd
CY2022	nlsp	Payment On Second Credit Facility PaymentOnSecondCreditFacility		usd
CY2020	nlsp	Payment On Second Credit Facility PaymentOnSecondCreditFacility		usd
CY2022	nlsp	Payment On Convertible Loans PaymentOnConvertibleLoans		usd
CY2020	nlsp	Payment On Convertible Loans PaymentOnConvertibleLoans		usd
CY2022	nlsp	Payment On Convertible Loans Related Party PaymentOnConvertibleLoansRelatedParty		usd
CY2020	nlsp	Payment On Convertible Loans Related Party PaymentOnConvertibleLoansRelatedParty		usd
CY2022	nlsp	Payment On Bridge Loan PaymentOnBridgeLoan		usd
CY2020	nlsp	Payment On Bridge Loan PaymentOnBridgeLoan		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2020	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	nlsp	Proceeds From Swiss Government Loan ProceedsFromSwissGovernmentLoan		usd
CY2021	nlsp	Proceeds From Swiss Government Loan ProceedsFromSwissGovernmentLoan		usd
CY2022	nlsp	Proceeds From Bridge Loan ProceedsFromBridgeLoan		usd
CY2021	nlsp	Proceeds From Bridge Loan ProceedsFromBridgeLoan		usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2020	nlsp	Cash Paid For Interest CashPaidForInterest		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2020	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022	nlsp	Issuance Of Common Shares To Consultant For Payment Of Expenses IssuanceOfCommonSharesToConsultantForPaymentOfExpenses		usd
CY2020	nlsp	Issuance Of Common Shares To Consultant For Payment Of Expenses IssuanceOfCommonSharesToConsultantForPaymentOfExpenses		usd
CY2022	nlsp	Issuance Of Common Shares To Yorkville For Partial Payment Of Commitment Fees IssuanceOfCommonSharesToYorkvilleForPartialPaymentOfCommitmentFees		usd
CY2020	nlsp	Issuance Of Common Shares To Yorkville For Partial Payment Of Commitment Fees IssuanceOfCommonSharesToYorkvilleForPartialPaymentOfCommitmentFees		usd
CY2022	nlsp	Debt Discount On Related Party Loans DebtDiscountOnRelatedPartyLoans		usd
CY2021	nlsp	Debt Discount On Related Party Loans DebtDiscountOnRelatedPartyLoans		usd
CY2022Q4	nlsp	Accrued Commitment Fee AccruedCommitmentFee		usd
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement		usd
CY2020	nlsp	Actuarial Loss Outside Corridor Recognized ActuarialLossOutsideCorridorRecognized		usd
CY2021	nlsp	Past Service Cost Recognized PastServiceCostRecognized		usd
CY2020	nlsp	Past Service Cost Recognized PastServiceCostRecognized		usd
CY2022	nlsp	Amortization Of Pension Related Net Loss AmortizationOfPensionRelatedNetLoss		usd
CY2021	nlsp	Amortization Of Pension Related Net Loss AmortizationOfPensionRelatedNetLoss		usd
CY2021Q4	nlsp	Prior Service Cost Beginning PriorServiceCostBeginning		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	nlsp	Other Deferred Tax Net OtherDeferredTaxNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001783036

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
nlsp-20221231_cal.xml	Edgar Link	unprocessable
nlsp-20221231_lab.xml	Edgar Link	unprocessable
0001213900-23-036920-index-headers.html	Edgar Link	pending
0001213900-23-036920-index.html	Edgar Link	pending
0001213900-23-036920.txt	Edgar Link	pending
0001213900-23-036920-xbrl.zip	Edgar Link	pending
f20f2022ex12-1_nlspharma.htm	Edgar Link	pending
f20f2022ex12-2_nlspharma.htm	Edgar Link	pending
f20f2022ex13-1_nlspharma.htm	Edgar Link	pending
f20f2022ex13-2_nlspharma.htm	Edgar Link	pending
f20f2022ex15-1_nlspharma.htm	Edgar Link	pending
f20f2022ex2-1_nlspharma.htm	Edgar Link	pending
f20f2022ex4-17_nlspharma.htm	Edgar Link	pending
f20f2022_nlspharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
f20f2022_nlspharma_htm.xml	Edgar Link	completed
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nlsp-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
nlsp-20221231_def.xml	Edgar Link	unprocessable
nlsp-20221231_pre.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NLSP
NLS Pharmaceutics Ltd. Stock $nlsp

2022 Q4 Form 20-F Financial Statement

#000121390023036920 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NLSP NLS Pharmaceutics Ltd. Stock $nlsp

2022 Q4 Form 20-F Financial Statement

#000121390023036920 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NLSP
NLS Pharmaceutics Ltd. Stock $nlsp